Inoculation of inactivated 146S foot-and-mouth disease virus particles into guineapigs elicited the formation of neutralizing antibody and the serum had a 10-fold higher titre in radioimmunoassay (RIA) with 146S particles than with the 12S virus subunit. In contrast, a single inoculation of the 12S subunit or the isolated polypeptide VP1 elicited the formation of antibody having a much lower titre in RIA with the 146S particle than with the 12S subunit and low or undetectable neutralizing activity. However, sera from guinea-pigs given two or more inoculations of the 12S subunit or VP1 had neutralizing activity. The level in the anti-VP1 serum was lower than that in the anti-12S serum and both were much lower than that in animals receiving two inoculations of the 146S particle. The neutralizing activity elicited by the three antigens was absorbed by the homologous antigen. In contrast, neither the 12S subunit nor VP1 absorbed the anti-146S neutralizing antibody and VPI did not absorb the anti-12S subunit neutralizing antibody. However, the 12S subunit partly absorbed the neutralizing activity elicited by VP 1. The results are compatible with a model in which the 146S particle elicits a spectrum of neutralizing antibodies which are completely absorbed by the homologous particle but only partially by the 12S subunit or VP1. The results are discussed in relation to the structural features required for the production of neutralizing antibody.
INTRODUCTION
The foot-and-mouth disease virus (FMDV) particle consists of one molecule of singlestranded RNA, mol. wt. approx. 2.6 × 106, and 60 copies each of four polypeptides, VP1, VP2 and VP3 with tool. wt. of 23 x 103 to 24 × 103 (Boothroyd et al., 1982) , and VP4 ofmol, wt. 8 x 103. The virus particle, which sediments at 146S, can be disrupted at pH values below 6.5 into the infectious RNA, an aggregate of VP4 molecules and a 12S subunit consisting of five copies of each of the polypeptides VP1, VP2 and VP3 (Vasquez et al., 1979) . Inoculation of a single dose of 1 to 5 p.g of the acetylethyleneimine (AEI)-inactivated 146S particle into cattle or guineapigs produces sufficient neutralizing antibody to provide protection against challenge. However, two doses containing at least 5 ~tg each of the 12S subunit are needed to produce the same level of neutralizing antibody. Since the immunizing antigen of the virus particle is associated with polypeptide VP1 (Wild et al., 1969; Laporte et al., 1973; Bachrach et al., 1975; Kaaden et al., 1977; Meloen et al., 1979) , the difference between the activities of the 146S particle and 12S subunit suggests that the configuration of VP1 on the two particles is different. Furthermore, differences exist between the 12S subunit and VP1 monomer isolated from virus particles because even larger amounts of VP1 are required to produce the same neutralizing antibody levels as the 12S subunit. For example, in pigs three doses of VP1, each containing 100 ~tg given with oily adjuvant at intervals of 28 days, gave a lower response than one dose containing 1 lxg of 146S particles (Bachrach et al., 1975) .
A similar low response has been obtained with VP1 expressed in Escherichia coli cells containing the appropriately modified plasmid (Kleid et al., 1981) . In one experiment with pigs, 0022-1317/82/0000-5276 $02.0001982 SGM for example, two inoculations 24 days apart of 140 Ixg VPI present as part of 250 I-tg of the expressed fusion protein gave the same level of neutralizing antibody as would be expected from an immunizing dose (about 1 ~tg) of the intact virus particle. Similar results have been obtained in cattle by the same authors and in goats by H. Kupper & M. Mussgay (personal communication) using another serotype of the virus.
In view of the potential value of a genetically engineered vaccine to the control of foot-andmouth disease, it is important to determine the reasons for the different responses of animals to the 146S, 12S and VP1 antigens. In particular, it seemed important to ascertain whether the difference in response was quantitative only or whether the neutralizing antibodies produced by the three antigens were qualitatively different.
METHODS
Antigens. Viruses of type O (strain BFS 1848 of subtype 1, strain 1 of subtype 6 and strain Thailand 1/80, subtype not yet determined), type A (strain 61 of subtype 10) and type C (strain Noville of subtype 1 ) were grown at 37 °C in monolayers of BHK-21 cells containing 108 cells in Eagle's medium. Supernatant fluids separated from the disintegrated cells had titres of approx. 107 LDso/0-03 ml in 7-day-old mice after intraperitoneal (i.p.) inoculation and contained about 1 I~g 146S particles/ml. Virus labelled with [3sS]methionine was obtained by infecting BHK-21 cell monolayers at a high multiplicity, removing the inoculum 1.5 h later and washing the monolayers three times with methionine-free Eagle's medium before adding 200 ~Ci [3sS]methionine (sp. act. 1050 Ci/mmol) in the same medium. The cell sheets disintegrated about 6 h after infection.
The 146S particles were purified by the method described by Brown & Cartwright (1963) . Preparations of the 12S subunit were obtained from the 146S particle preparations by lowering the pH to 6.5 and then centrifuging in a sucrose gradient. Polypeptide VP1 was prepared by heating 146S particles at 100 °C for 5 min in the presence of 1% SDS and 1% 2-mercaptoethanol. The four virus polypeptides were then separated by polyacrylamide gel electrophoresis (PAGE) and the band of VPI was eluted from the gel electrophoretically. The preparation appeared as a single band on analysis by PAGE.
Antisera. All the preparations inoculated into guinea-pigs were first inactivated by incubating with 0.05 % AEI at 37 °C for 6 h. The reaction was stopped by adding 2% sodium thiosulphate. The antigens were mixed with AI(OH) 3 gel or Freund's complete adjuvant and inoculated subcutaneously.
Neutralization tests. These were carried out by mixing 10-fold dilutions of virus in 0.04 M-phosphate with an equal volume of 0.04 M-phosphate pH 7.6 or an antiserum dilution in the same buffer at 4 °C for 18 h. Aliquots (0.03 ml} of the mixtures were then inoculated i.p. into groups of 4-to 7-day-old mice. The differences between the logto LDs, values of the control and test sera were taken as the neutralization indices of the sera.
Radioimmunoassay (RIA).
[3 sS]methionine.labelled 146S particles, or their equivalent weight converted to 12S subunits, were mixed with increasing twofold dilutions of homologous antiserum in 0.15 M-NaCI, 0.005 M-EDTA, 0-05 M-Tris HC1 pH 7-5 containing 0.05% Nonidet P40 and 0.05% normal guinea-pig serum. After 2 h at 37 °C, the antigen antibody complexes were precipitated with excess rabbit anti-guinea-pig globulin (Burroughs Wellcome, Beckenham, U.K.). The reciprocal of the serum dilution which precipitated 50% of the radioactive antigen was taken as the serum titre.
In some experiments, the antigen-antibody complexes were precipitated with anti-species serum or with formalin-fixed Staphylococcus aureus ghosts bearing protein A (Pansorbin; Calbiochem-Behring Corporation, La Jolla, Ca., U.S.A.).
Competition RIA. To estimate the ability of the 12S subunit to compete with the 146S particle for antibody raised to the 146S particle, the dilution of anti-146S particle serum which precipitated 70 % of the radioactivity in a preparation of [3 sS]methionine_labelled 146S particles was mixed with fivefold increasing weights of non-radioactive 146S particle or 12S subunit preparations. After 18h at 4 °C, the radioactive 146S particle preparation was added and 4 h later the antigen-antibody complexes were precipitated as described above. The percentage of radioactive label remaining in the supernatant was then measured. In similar experiments using the dilution of anti-12S serum required to precipitate 70% of the radioactivity in a preparation of the 12S subunit, the competition of the anti-146S antigen for the 12S serum was measured.
RESULTS

Antibody response to the inoculation of the 146S particle, the 12S subunit and polypeptide VP1
In experiments with the type A virus sera obtained 21 days after inoculating guinea-pigs with 1 lag of the 146S particle (approx. 0-2 ~tg VP1) or 0.6 ~tg of 12S subunit (approx. 0-2 ~tg VP1) or 4.5 ~tg of isolated polypeptide VPI were tested by RIA. The results in Fig. 1 t Sera were diluted 10-fold for the test.
RIA titre of the anti-146S particle serum against 146S particles was 800 compared with about 100 against 12S subunit with the same specific activity. Whether the antibody reacting with the 12S subunit is elicited by 146S particles or by 12S subunits formed by breakdown of 146S particles in the host animal has still to be determined. Conversely, the RIA titre of the anti-12S serum was about 200 against the 12S subunit compared with approx. 20 against 146S particles (Fig. 1 b) . The titre of the anti-VP1 serum was 128 against 12S subunit compared with 32 against the 146S particle (Fig. 1 c) . It is noteworthy that to obtain a reaction with the anti-VP 1 serum higher specific activity antigens were required than in the two previous tests.
In experiments to compare the neutralizing activity elicited by the three antigens, a purified 146S particle preparation of type O (subtype 6) was inactivated with AEI and inoculated into guinea-pigs. The anti-146S particle serum neutralized the virus. In the mouse neutralization test, 2.9 log10 of virus were neutralized by 0.015 ml of 1/10 antiserum. In contrast, the antisera produced by inoculation of a similar or greater amount of the 12S subunit or polypeptide VP1 respectively had low or undetectable neutralizing activity (Table 1) . Our experience over many years has been that the level of neutralizing antibody produced by inoculation of the 12S subunit is considerably lower than that produced by the 146S particle and in the present experiments the neutralizing antibody produced was below the level of detection. Similarly, our experience with many preparations of VP1 has been that no neutralizing antibody is detected with one inoculation of the polypeptide. After a second inoculation of the 12S subunit or VP1 the antibody response increased. In most animals, the RIA titres of these sera to the 146S particle increased to a level that surpassed that of the titre to the 12S subunit. The neutralizing activity of the sera, although now measurable, was much lower than that of animals which had received two inoculations of the 146S particle (Table 1) .
Competition experiments
The ability of the 12S subunit and 146S particles to inhibit the reaction of each particle with its homologous antiserum (produced by one inoculation) was measured by competition RIA. A 1/600 dilution of anti-146S particle serum, chosen because this amount of antiserum does not have a detectable titre with the 12S antigen (see Fig. 1 a) , was allowed to react with serial fivefold dilutions of the 146S particle and 12S subunit for 18 h at 4 °C. The amount of unabsorbed serum was then determined by its ability to precipitate a PSS]methionine-labelled 146S particle preparation. Fig. 2 (a) shows that, at the 50 % inhibition level, about 100 times more of the 12S subunit was required to prevent the anti-146S particle serum precipitating the 35S-labelled particles. In similar experiments with a 1/160 dilution of the anti-12S subunit serum (Fig. 1 b) , the 146S particle preparation did not compete in the reaction of the 12S subunit with its homologous antiserum (Fig. 2b) .
Cross-reaction of VP1 and the 146S particle with homologous and heterologous antisem
Reaction of pSS]methionine-labeUed 146S particles of type O (subtype 6) with homologous antiserum followed by adsorption on to and elution from Pansorbin resulted in 90 % of the radioactivity being associated with the antibody. When the same weight of 3 sS_labelled VP 1 was used with the same amount of antiserum, only 6~ of the radioactivity became associated with the antibody. In contrast, 40~ of a VP1 preparation was precipitated by an anti-VP1 serum which precipitated only 4~ of the 146S particle. These results show that the cross-reactions between VP 1 and 146S particles and the two heterologous antisera are much lower than the homologous reactions.
Nature of the neutralizing antibody in antisera produced against the 12S subunit and VP1
Although one inoculation of the 12S subunit or VP1 does not usually produce measurable neutralizing antibody, low levels are produced by two or more inoculations. It was important to determine whether this activity was qualitatively similar to the neutralizing activity produced by 146S particles. Antisera to the 146S particle, 12S subunit and VP1 were each absorbed with 4.5 -* The 146S, 12S and VP1 antigens used in this test were prepared from the same batch of 146S particles so that the corresponding dilutions contained equivalent numbers of the VP1 polypeptide. serial dilutions of the 146S particle, 12S subunit and VP1 and the residual neutralizing activity was measured by titration in mice.
The results show that the 146S particle absorbs the neutralizing activity of all the antisera (Table 2) . This is to be expected since the property being examined, namely neutralization, is the ability to react with the 146S particle. The 12S subunit absorbed its homologous antiserum but did not reduce the antibody titre of the anti-146S particle serum. However, it reduced the titre of the anti-VP 1 serum. Polypeptide VP 1 did not reduce the titres of anti-146S particle and anti-12S subunit sera but it did absorb the neutralizing activity of the homologous antiserum. These results suggest that the neutralizing antibodies elicited by the 12S subunit and VP1 form only a portion of the spectrum of antibodies produced by the 146S particle.
Heterotypic reactions with the 12S subunit and VP1 antisera
Vaccines prepared from individual virus types do not elicit heterotypic neutralizing antibody and do not protect animals against heterotypic challenge. Indeed, in some instances animals are not protected against challenge by virus strains of the same serotype. In one report, however, Meloen & Briaire (1980) demonstrated a degree of neutralization of a virus of serotype A by the serum of a rabbit inoculated with VP1 prepared from a virus of serotype O. This report has stimulated interest in the spectrum of protection which may be afforded by VP1 isolated from virus particles or produced in E. coli cells. Consequently, we have compared the activity of antisera elicited by the 146S particle, 12S subunit or VPI of virus of type O (subtype 1) in neutralization tests with another subtype of type O and with virus isolates of types A and C. The 
Antiserum
O-1 strain BFS 0-6 strain 1 O-Thailand A61 C Noville 146S 3.1 2-3 0-7 -0"2 -0.1 12S 3.9 2"7 0"5 -0.4 -0.1 VP1 2'3 1-9 0"7 0 0'3 * The anti-146S serum was diluted 1/1000; the anti-12S and -VP1 sera were used at a dilution of 1/10. results of our experiments show that guinea-pig antisera to the 12S subunit and VP1 had the same specificity as that found in sera from animals inoculated with the 146S particle (Table 3) .
DISCUSSION
The major immunizing site on the FMDV particle is associated with polypeptide VP1. However, the neutralizing antibody response to the isolated VP1 is very low compared with that obtained with much smaller amounts of the intact virus particles. It could be argued that the methods which have been used to isolate VP1 from virus particles are so harsh that the polypeptide is denatured, resulting in its low activity. However, the 12S subunit, which consists of five copies of each of VP1, VP2 and VP3 and can be obtained under mild conditions simply by lowering the pH of the virus suspension to 6.5, also has low immunizing activity. It is likely that configurational changes account for the low activity of the VP1 polypeptide and 12S subunit, for example an alteration in the secondary or tertiary structure of individual VP1 molecules or a change in the quaternary structure of the group of five VP1 molecules arranged around the vertices of the virion. Such an arrangement of the VP1 polypeptides, which was proposed by Dunker (1979) as a model for picornaviruses, is based on the results of proteinprotein cross-linking experiments with Mengo virus (Hordern et al., 1979) and probably applies to FM DV, particularly in view of the electron microscopic observations of Vasquez et al. (1979) .
Further evidence for considering the importance of the configuration of VP1 for the maximum production of neutralizing antibody has recently been obtained from experiments with a genetically engineered polypeptide. Kleid et al. (1981) and H. Kupper, M. Mussgay and their colleagues (personal communication) have shown that the immunizing activity of VP1 expressed in E. coli cells is no higher than that of an equal weight of VP1 produced from disrupted virus particles.
The purpose of the present investigation was to study the nature of the antibodies elicited by inoculation of the 146S particle, 12S subunit and polypeptide VP1. Our results show that one inoculation of 146S particles produces a measurable neutralizing antibody response. One inoculation of the isolated VP 1 or 12S subunit elicits an antibody (or antibodies) which reacts to a higher titre with the 12S subunit than with the 146S particles. A second inoculation of either antigen then produces increased titres to the 12S subunit and to the 146S particle, the titre to the 146S particle usually being higher. Moreover, after a second inoculation there is detectable neutralizing activity in the anti-12S subunit serum. Although this neutralizing antibody can be absorbed from the anti-12S serum by the 12S subunit, it has been assumed that, since hosts having multiple inoculations of 12S or VP1 are protected from challenge by homotypic virus, the neutralizing antibodies produced by the 12S subunit and VP1 are subsets of the polyclonal neutralizing antibodies elicited by the 146S particle.
The finding that a primary inoculation of 12S subunit or VP1 fails to elicit antibody capable of reacting with the 146S particles was confirmed in precipitation experiments. One inoculation of VP1 produces an antibody capable of reacting with this polypeptide. Similarly, antibody produced by inoculating the virus particle precipitates the virus. However, neither of the two sera reacts well with the heterologous antigen and indeed multiple inoculations of VP1 are needed to induce measurable amounts of antibody capable of neutralizing the 146S particle.
We conclude that the 146S particle possesses an antigenic site which triggers the lymphocytes capable of producing neutralizing antibody. In contrast, the 12S subunit and VP1, on primary inoculation, produce mainly non-neutralizing antibodies which fail to react with the 146S particle. Because of the similarity of the 146S and 12S antigens (Cartwright et al., 1980 (Cartwright et al., , 1982 , this primary stimulation activates at least part of the spectrum of B-lymphocytes capable of producing neutralizing antibody. Subsequent inoculations of 12S subunit or VP1 then activate the progeny of these cells.
A recent publication by Icenogle et al. (1981) possibly demonstrates a similar situation with another picornavirus. They showed that a monoclonal, neutralizing antibody to poliovirus failed to react with the 5S protomeric units but reacted with the 5S units when they took up the 14S configuration. This suggests that no component on the 5S protomer is recognized by the particular monoclonal neutralizing antibody but when the 5S subunits assemble recognition is then indicated by the antigen-antibody reaction. This might be considered analogous to the failure of anti-146S serum to recognize isolated VP1 although it recognizes the 12S subunit.
If, as our hypothesis suggests, there are differences in the antigenic structure of the immunogen on the 146S particle, the 12S subunit and VP1, it means that the configuration of VP1, whether produced from virus particles or as a fusion protein in E. coli cells, is different from that exhibited on the virus particle. We have provided a possible explanation why VP1 and the 12S subunit produce only low levels of neutralizing antibody. However, further studies to determine the relationship and efficiency of the antigenic structures that activate lymphocytes capable of producing neutralizing antibody are required before it will be possible to explain and engineer what constitutes an efficient vaccine for foot-and-mouth disease.
